Back to today’s briefing

Story perspectives

Vertex's Zimislecel Trial Could Revolutionize Diabetes Treatment

4/24/2025

38 5

Summary

Story summary

Vertex Pharmaceuticals is making strides in the fight against severe type 1 diabetes with its phase 3 trial of zimislecel, an innovative stem cell therapy. Targeting 50 patients by 2025, the trial will evaluate insulin independence and safety over five years. A successful outcome could transform the lives of 60,000 patients, building on recent FDA approval of a similar treatment.

1 of 1

Story summary

Vertex Pharmaceuticals is making strides in the fight against severe type 1 diabetes with its phase 3 trial of zimislecel, an innovative stem cell therapy. Targeting 50 patients by 2025, the trial will evaluate insulin independence and safety over five years. A successful outcome could transform the lives of 60,000 patients, building on recent FDA approval of a similar treatment.